当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Ilyas Khan
Ebola virus is associated with adverse indirect effects since resources are diverted from programs aimed at controlling important diseases such as malaria, tuberculosis, and HIV infection. We hypothesize that a significant burden of Ebola viral disease if undetected may lead to missed opportunities for prevention and heighten the risk for large-scale outbreaks and pandemics. Further, Ebola is associated with high fatality rate and significant socioeconomic impact. Therefore, the need for a rapid diagnostic technique to be used at the point of care, universal Polyvalent-Ebola virus vaccine, and effective anti-Ebola drug cannot be overemphasized. Thus, this review focuses on the availability, suitability, and significance of current advances in diagnostics, vaccines, and therapeutic options for the Ebola disease and the need to develop novel vaccines and antiviral therapies that are effective against all known Ebola virus species. The disease is considered among the top five most dangerous diseases, as captured in the list of prioritized diseases. The significance of Ebola hemorrhagic fever lies on its morbidity, the splanchnic manner in which it kills the high mortality rate and absence of efficacious drugs. As such, Ebola virus disease has become a global public health burden that has led to major epidemics in resource-poor settings and posing an imminent threat of global pandemics. Thus, the Ebola virus is identified as a bio-safety level-4 pathogen and CDC category A-agents of bioterrorism.